Dearborn Partners LLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 11.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 121,508 shares of the medical instruments supplier's stock after selling 15,571 shares during the period. Dearborn Partners LLC's holdings in Becton, Dickinson and Company were worth $27,833,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of the stock. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Becton, Dickinson and Company by 50.6% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after purchasing an additional 27,581 shares in the last quarter. Foster Victor Wealth Advisors LLC bought a new position in Becton, Dickinson and Company in the 1st quarter valued at about $6,406,000. GAMMA Investing LLC lifted its position in Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock valued at $744,000 after acquiring an additional 748 shares in the last quarter. Finally, Ritholtz Wealth Management purchased a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $224,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research firms have commented on BDX. Morgan Stanley decreased their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Barclays lowered their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Bank of America cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target on the stock. in a report on Thursday, May 1st. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a report on Friday, May 2nd. Finally, Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of "Hold" and a consensus target price of $219.22.
Get Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Price Performance
Shares of BDX traded down $2.06 during mid-day trading on Friday, reaching $176.19. 4,688,991 shares of the stock traded hands, compared to its average volume of 2,814,753. The firm has a fifty day moving average price of $174.93 and a 200 day moving average price of $200.87. The company has a market cap of $50.50 billion, a price-to-earnings ratio of 33.62, a price-to-earnings-growth ratio of 1.35 and a beta of 0.25. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the previous year, the business earned $3.17 earnings per share. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.4%. Becton, Dickinson and Company's payout ratio is 79.39%.
Insider Buying and Selling at Becton, Dickinson and Company
In related news, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Shan sold 1,166 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is currently owned by insiders.
Becton, Dickinson and Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
